These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22056470)

  • 1. Detection of nuclear matrix protein 22 and survivin baseline level in patients after radical cystectomy.
    Dong ZL; Lu ZP; Wang HZ; Zhang LY; Wang ZP; Zhang YF; Ma BL
    Urol Int; 2011; 87(4):445-9. PubMed ID: 22056470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
    Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients.
    Stein JP; Clark P; Miranda G; Cai J; Groshen S; Skinner DG
    J Urol; 2005 Apr; 173(4):1163-8. PubMed ID: 15758728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection.
    Miyanaga N; Akaza H; Tsukamoto S; Shimazui T; Ohtani M; Ishikawa S; Noguchi R; Manabe F; Nishijima Y; Kikuchi K; Sato K; Hayashi H; Kondo F; Shiraiwa H; Aoyama O
    Int J Clin Oncol; 2003 Dec; 8(6):369-73. PubMed ID: 14663639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
    Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
    J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
    Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer.
    Stein JP; Penson DF; Lee C; Cai J; Miranda G; Skinner DG
    J Urol; 2009 May; 181(5):2052-8; discussion 2058-9. PubMed ID: 19286213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
    Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
    Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
    Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
    Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H; Kor K; Djalali M
    Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer.
    Davies B; Chen J; Modugno F; Weissfeld J; Landsittel D; Dhir R; Nelson J; Getzenberg RH
    J Urol; 2005 Nov; 174(5):1767-70. PubMed ID: 16217280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
    Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
    BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
    Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
    BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature.
    Stein JP; Penson DF; Wu SD; Skinner DG
    J Urol; 2007 Sep; 178(3 Pt 1):756-60. PubMed ID: 17631333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.